Cardiol Therapeutics
CRDL
35 hedge funds and large institutions have $3.54M invested in Cardiol Therapeutics in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 7 closing their positions.
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
9% more funds holding
Funds holding: 32 → 35 (+3)
0.53% more ownership
Funds ownership: 10.8% → 11.32% (+0.53%)
3% less capital invested
Capital invested by funds: $3.64M → $3.54M (-$95.1K)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AXS Investments
Port Chester,
New York
|
+$1.02M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$63K |
| 3 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$46.7K |
| 4 |
LNWTC
Laird Norton Wetherby Trust Company
Seattle,
Washington
|
+$36.3K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$35.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$557K |
| 2 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
-$118K |
| 3 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
-$74.8K |
| 4 |
Goldman Sachs
New York
|
-$45.5K |
| 5 |
Jane Street
New York
|
-$25K |
CRDL Hedge Fund Activity: Q1 2023 in Review
35 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Cardiol Therapeutics (CRDL) for Q1 2023, worth a combined $3.54M — down 2.6% from $3.64M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CRDL positions and 7 closed out — a net gain of 3 holders — while 4 added to existing stakes and 6 trimmed.
The largest buyer was AXS Investments, opening a new position worth an estimated $1.02M. The largest seller was Mirae Asset Global Investments, exiting entirely with an estimated $557K sold.
- 35 institutional investors held Cardiol Therapeutics (CRDL) as of Q1 2023, up from 32 in Q4 2022.
- Funds reported $3.54M of Cardiol Therapeutics stock for Q1 2023, down 2.6% quarter-over-quarter.
- 10 funds opened new Cardiol Therapeutics positions in Q1 2023 and 7 closed out, a net change of +3 holders.
- The largest Cardiol Therapeutics buyer in Q1 2023 was AXS Investments, an estimated $1.02M added.
- The largest Cardiol Therapeutics seller in Q1 2023 was Mirae Asset Global Investments, an estimated $557K sold.
Based on aggregated 13F filings for Q1 2023.